NASDAQ:MYOK - Myokardia Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$58.30 +1.00 (+1.75 %)
(As of 08/22/2018 01:37 AM ET)
Previous Close$57.30
Today's Range$57.00 - $58.85
52-Week Range$32.80 - $63.00
Volume118,100 shs
Average Volume386,197 shs
Market Capitalization$2.27 billion
P/E Ratio-41.50
Dividend YieldN/A
Beta3.5
Myokardia logoMyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which has completed Phase II clinical trial that is designed to reduce left ventricular contractility to potentially alleviate the functional consequences and symptoms of hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression. The company also develops MYK-491, an orally-administered small molecule, which is in Phase I b clinical trial that is designed to restore normal contractility in the diseased dilated cardiomyopathy (DCM) heart. Its three preclinical programs include HCM-2 that is used to reduce cardiac muscle contractility to normal levels in HCM patients; DCM-2, which is used to enhance cardiac muscle contractility to normal levels in genetic DCM patients; and LUS-1 that is used to counteract a muscle disruption that results in impaired relaxation of the heart, a biomechanical defect found in specific HCM and genetic DCM patient subgroups, as well as in other less common heritable cardiomyopathies. The company has a strategic collaboration with Aventis Inc. for the research, development, and commercialization of pharmaceutical products to treat, prevent, and diagnose HCM and DCM, as well as additional indications. MyoKardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.

Receive MYOK News and Ratings via Email

Sign-up to receive the latest news and ratings for MYOK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MYOK
CUSIPN/A
Phone650-741-0900

Debt

Debt-to-Equity RatioN/A
Current Ratio8.53
Quick Ratio8.53

Price-To-Earnings

Trailing P/E Ratio-41.50
Forward P/E Ratio-28.30
P/E GrowthN/A

Sales & Book Value

Annual Sales$22.50 million
Price / Sales103.96
Cash FlowN/A
Price / CashN/A
Book Value$6.76 per share
Price / Book8.62

Profitability

EPS (Most Recent Fiscal Year)($1.40)
Net Income$-45,950,000.00
Net Margins-249.22%
Return on Equity-21.16%
Return on Assets-18.19%

Miscellaneous

Employees102
Outstanding Shares40,120,000
Market Cap$2.27 billion

Myokardia (NASDAQ:MYOK) Frequently Asked Questions

What is Myokardia's stock symbol?

Myokardia trades on the NASDAQ under the ticker symbol "MYOK."

How were Myokardia's earnings last quarter?

Myokardia Inc (NASDAQ:MYOK) released its quarterly earnings results on Wednesday, August, 8th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.50) by $0.01. The biotechnology company earned $6.64 million during the quarter, compared to analysts' expectations of $6.32 million. Myokardia had a negative return on equity of 21.16% and a negative net margin of 249.22%. View Myokardia's Earnings History.

When is Myokardia's next earnings date?

Myokardia is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for Myokardia.

What price target have analysts set for MYOK?

7 brokers have issued 1-year target prices for Myokardia's stock. Their predictions range from $64.00 to $83.00. On average, they anticipate Myokardia's share price to reach $73.5714 in the next year. This suggests a possible upside of 26.2% from the stock's current price. View Analyst Price Targets for Myokardia.

What is the consensus analysts' recommendation for Myokardia?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myokardia in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myokardia.

Who are some of Myokardia's key competitors?

Who are Myokardia's key executives?

Myokardia's management team includes the folowing people:
  • Mr. Tassos Anastasios Gianakakos, Pres, CEO & Director (Age 45)
  • Dr. June Lee, COO & Chief Devel. Officer (Age 52)
  • Dr. Robert S. McDowell, Chief Scientific Officer (Age 60)
  • Dr. Charles J. Homcy, Advisor (Age 70)
  • Dr. Eric J. Topol, Advisor (Age 64)

Has Myokardia been receiving favorable news coverage?

News articles about MYOK stock have been trending somewhat positive on Tuesday, Accern reports. The research group identifies negative and positive press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Myokardia earned a news impact score of 0.21 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 45.27 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for Myokardia.

Who are Myokardia's major shareholders?

Myokardia's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (16.65%), BlackRock Inc. (7.30%), Partner Fund Management L.P. (4.53%), Hillhouse Capital Management Ltd. (2.14%), Casdin Capital LLC (1.94%) and BB Biotech AG (1.33%). Company insiders that own Myokardia stock include Anastasios Gianakakos, Jake Bauer, Joseph Lambing, Kevin P Starr, Rock Ventures Ii LP Third, Sanofi and Wendy L Yarno. View Institutional Ownership Trends for Myokardia.

Which institutional investors are selling Myokardia stock?

MYOK stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BlueMountain Capital Management LLC, Victory Capital Management Inc., Alps Advisors Inc., WINTON GROUP Ltd, Bank of America Corp DE, Tortoise Investment Management LLC and Chartwell Investment Partners LLC. Company insiders that have sold Myokardia company stock in the last year include Anastasios Gianakakos, Jake Bauer, Joseph Lambing, Kevin P Starr and Rock Ventures Ii LP Third. View Insider Buying and Selling for Myokardia.

Which institutional investors are buying Myokardia stock?

MYOK stock was purchased by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., BlackRock Inc., FMR LLC, BB Biotech AG, Millennium Management LLC, Casdin Capital LLC, grace capital and Federated Investors Inc. PA. Company insiders that have bought Myokardia stock in the last two years include Sanofi and Wendy L Yarno. View Insider Buying and Selling for Myokardia.

How do I buy shares of Myokardia?

Shares of MYOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Myokardia's stock price today?

One share of MYOK stock can currently be purchased for approximately $58.30.

How big of a company is Myokardia?

Myokardia has a market capitalization of $2.27 billion and generates $22.50 million in revenue each year. The biotechnology company earns $-45,950,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Myokardia employs 102 workers across the globe.

How can I contact Myokardia?

Myokardia's mailing address is 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-741-0900 or via email at [email protected]


MarketBeat Community Rating for Myokardia (NASDAQ MYOK)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  159 (Vote Outperform)
Underperform Votes:  165 (Vote Underperform)
Total Votes:  324
MarketBeat's community ratings are surveys of what our community members think about Myokardia and other stocks. Vote "Outperform" if you believe MYOK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel